CTLA4 and melanoma: Combination 90Y-NM600 and anti-CTLA4 therapy increased CD8+ and effector memory CD8+ T cells in B78 melanoma tumors 25 days following 2.5 Gy TRT, but TRT monotherapy did not affect CD8+ populations [53].